Tove Olafsen

3.5k total citations
69 papers, 2.7k citations indexed

About

Tove Olafsen is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Tove Olafsen has authored 69 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Radiology, Nuclear Medicine and Imaging, 26 papers in Oncology and 22 papers in Molecular Biology. Recurrent topics in Tove Olafsen's work include Monoclonal and Polyclonal Antibodies Research (40 papers), Radiopharmaceutical Chemistry and Applications (35 papers) and Medical Imaging Techniques and Applications (10 papers). Tove Olafsen is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (40 papers), Radiopharmaceutical Chemistry and Applications (35 papers) and Medical Imaging Techniques and Applications (10 papers). Tove Olafsen collaborates with scholars based in United States, Norway and Sweden. Tove Olafsen's co-authors include Anna M. Wu, Vania Kenanova, Andrew Raubitschek, Lawrence E. Williams, Sanjiv S. Gambhir, John E. Shively, Felix B. Salazar, Paul J. Yazaki, Kirstin A. Zettlitz and Lars Norderhaug and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Tove Olafsen

69 papers receiving 2.6k citations

Peers

Countries citing papers authored by Tove Olafsen

Since Specialization

Citations

This map shows the geographic impact of Tove Olafsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tove Olafsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tove Olafsen more than expected).

Fields of papers citing papers by Tove Olafsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tove Olafsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tove Olafsen. The network helps show where Tove Olafsen may publish in the future.

Co-authorship network of co-authors of Tove Olafsen

This figure shows the co-authorship network connecting the top 25 collaborators of Tove Olafsen. A scholar is included among the top collaborators of Tove Olafsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tove Olafsen. Tove Olafsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract A088: Radiopharmaceutical therapy for pancreatic cancer: Engineered anti-prostate stem cell antigen (PSCA) antibody demonstrates targeted imaging and antitumor effects in a syngeneic mouse model of pancreatic ductal adenocarcinoma (PDAC) 2024 ·Cancer Research ·(unknown), (unknown), Felix B. Salazar, (unknown), Masoud Farshbaf, (unknown), (unknown), Teresa Hong, Paul J. Yazaki, Tove Olafsen, Kirstin A. Zettlitz, Anna M. Wu	2
2	Multimodality PET and Near-Infrared Fluorescence Intraoperative Imaging of CEA-Positive Colorectal Cancer 2023 ·Molecular Imaging and Biology ·Thinzar M. Lwin, (unknown), (unknown), (unknown), Teresa Hong, (unknown), Tove Olafsen, Erasmus Poku, Michael Bouvet, Yuman Fong, John E. Shively, Paul J. Yazaki	7
3	Heart Uptake of [18F]Fluoro-4-Thia-Oleate in a Non-Alcoholic Fatty Liver Disease Mouse Model 2022 ·Pharmaceuticals ·(unknown), Weidong Hu, Jiangling Peng, Patty Wong, Fouad Kandeel, Tove Olafsen, John E. Shively	5
4	A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer 2021 ·Molecular Therapy — Methods & Clinical Development ·Shyambabu Chaurasiya, Annie Yang, Zhifang Zhang, Jianming Lü, (unknown), Sang‐In Kim, Yanghee Woo, Susanne G. Warner, Tove Olafsen, Yuqi Zhao, Xiwei Wu, Seymour Fein, (unknown), (unknown), Nicholas J. Ede, Yuman Fong	5
5	Identification of miRNA signatures associated with radiation-induced late lung injury in mice 2020 ·PLoS ONE ·Claude J. Rogers, Agnès Lukaszewicz, (unknown), Ewa D. Micewicz, Josephine A. Ratikan, (unknown), Thomas A. Miller, Christine Nguyen, Jason T. Lee, Tove Olafsen, Keisuke S. Iwamoto, William H. McBride, Dörthe Schaue, (unknown)	29
6	Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors 2020 ·EJNMMI Research ·Tom Bäck, Karin Jennbacken, (unknown), Sture Lindegren, Holger Jensen, Tove Olafsen, Paul J. Yazaki, Stig Palm, Per Albertsson, Jan‐Erik Damber, Anna M. Wu, Karin Welén	26
7	Immuno-PET of Murine T Cell Reconstitution Postadoptive Stem Cell Transplantation Using Anti-CD4 and Anti-CD8 Cys-Diabodies 2015 ·Journal of Nuclear Medicine ·Richard Tavaré, Melissa McCracken, Kirstin A. Zettlitz, Felix B. Salazar, Tove Olafsen, Owen N. Witte, Anna M. Wu	91
8	Fc Engineering: Serum Half-Life Modulation Through FcRn Binding 2012 ·Methods in molecular biology ·Tove Olafsen	21
9	The Soluble Serum Protein Gas6 Bridges Virion Envelope Phosphatidylserine to the TAM Receptor Tyrosine Kinase Axl to Mediate Viral Entry 2011 ·Cell Host & Microbe ·Kouki Morizono, Yiming Xie, Tove Olafsen, Benhur Lee, Asim Dasgupta, Anna M. Wu, Irvin S. Y. Chen	159
10	ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies) 2010 ·Protein Engineering Design and Selection ·Tove Olafsen, Shannon J. Sirk, David J. Betting, Vania Kenanova, (unknown), (unknown), Andrew Raubitschek, John M. Timmerman, Anna M. Wu	35
11	Antibody Vectors for Imaging 2010 ·Seminars in Nuclear Medicine ·Tove Olafsen, Anna M. Wu	171
12	Cys-diabody Quantum Dot Conjugates (ImmunoQdots) for Cancer Marker Detection 2009 ·Bioconjugate Chemistry ·Bhaswati Barat, Shannon J. Sirk, Katelyn E. McCabe, Jianqing Li, Eric J. Lepin, Roland Remenyi, Ai Leen Koh, Tove Olafsen, Sanjiv S. Gambhir, Shimon Weiss, Anna M. Wu	49
13	Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPT 2009 ·Journal of Experimental & Clinical Cancer Research ·Sepideh Afshar, Tove Olafsen, Anna M. Wu, Sherie L. Morrison	10
14	Recombinant Anti-CD20 Antibody Fragments for Small-Animal PET Imaging of B-Cell Lymphomas 2009 ·Journal of Nuclear Medicine ·Tove Olafsen, David J. Betting, Vania Kenanova, Felix B. Salazar, (unknown), Jonathan Said, Andrew Raubitschek, John M. Timmerman, Anna M. Wu	63
15	Site-Specific, Thiol-Mediated Conjugation of Fluorescent Probes to Cysteine-Modified Diabodies Targeting CD20 or HER2 2008 ·Bioconjugate Chemistry ·Shannon J. Sirk, Tove Olafsen, Bhaswati Barat, (unknown), Anna M. Wu	42
16	Engineered Antibody Fragments with Infinite Affinity as Reporter Genes for PET Imaging 2008 ·Journal of Nuclear Medicine ·Wei Liu, Tove Olafsen, Caius G. Radu, Isabel J. Hildebrandt, Mark R. McCoy, Michael E. Phelps, Claude F. Meares, Anna M. Wu, Johannes Czernin, Wolfgang Weber	35
17	The Pursuit of a Scalable Nanofabrication Platform for Use in Material and Life Science Applications 2008 ·Accounts of Chemical Research ·Stephanie E. A. Gratton, Stuart Williams, Mary E. Napier, Patrick D. Pohlhaus, Zhilian Zhou, Kenton B. Wiles, Benjamin W. Maynor, Clifton K.-F. Shen, Tove Olafsen, Edward T. Samulski, Joseph M. DeSimone	110
18	Recombinant chimeric OKT3 scFv IgM antibodies mediate immune suppression while reducing T cell activationin vitro 2001 ·European Journal of Immunology ·(unknown), Concepción de Inés, (unknown), Björn Cochlovius, (unknown), Tove Olafsen, Inger Sandlie, Melvyn Little	12
19	IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells 1998 ·Immunotechnology ·Tove Olafsen, Ingunn B. Rasmussen, Lars Norderhaug, Øyvind S. Bruland, (unknown)	13
20	Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Location of lysine residues and implications for radiolabeling 1995 ·Nuclear Medicine and Biology ·Tove Olafsen, Øyvind S. Bruland, Michael R. Zalutsky, Inger Sandlie	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact